Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for fourth quarter and fiscal year 2019 following the close of market on Wednesday, January 29, 2020.
On the same day, at
Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of technology and partnership
Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Roche, a global pioneer in pharmaceuticals and diagnostics, today announced a 15-year
Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed two additional patent infringement suits relating to BGI’s sequencing products, including the DNBSeq-400 (also known as MGISeq-2000)
Illumina, Inc. (NASDAQ:ILMN) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that they have mutually agreed to terminate their merger agreement, previously announced on
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invite investors to participate via webcast.
J.P. Morgan Healthcare
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.
Evercore ISI HealthCONx
English
Deutsch
